After using the AKT inhibitor LY294002, we found that LY294002 inhibited the levels of GPX4, GSH, FTH1, and xCT, and promoted an increase in HO-1, ROS, and Fe2+ content in HCC cells, but these results were reversed after overexpressing MELK. This evidence concerns the gene AKT1 and hepatocellular carcinoma.